BioSpace News Archive

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to continued public health concerns relating to COVID-19 and to prioritize the health and well-being of meeting participants.

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation.

Two Quebec Companies Joined Forces to Make Healthcare Mask for our “Guardian Angels”

Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its XCART™ CAR T therapy platform

CoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the first quarter of 2020 ended March 31, 2020 and provided an update on the Company’s recent and future developments.

Heat Biologics, Inc., a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, provided financial, clinical and operational updates for the first quarter ended March 31, 2020.

Genentech and the Genentech Foundation are announcing charitable commitments of $42 million to help address the devastating impact of the COVID-19 pandemic.

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.